Gilead/Kite Gain Second CAR-T Approval With Tecartus, Price On Par With Their First
Similar CAR-T Will Carry The Same Cost As Yescarta
Executive Summary
As the first company with two approved chimeric antigen receptor T-cell therapies, Gilead’s Kite subsidiary has set a precedent by keeping the pricing the same as its first approved CAR-T, Yescarta.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
ADC’s Phase II Data May Position ‘Lonca’ To Compete With Roche’s Polivy
The antibody-drug conjugate yields a 48% overall and 24% complete response rate in a pivotal Phase II DLBCL study. The Swiss biotech hopes to compete with Polivy and is studying combo therapy with Imbruvica.
ASCO 2020: BCMA CAR-T Race Heats Up Between Bristol And Janssen
The gap between potential approvals for Bristol’s ide-cel and Janssen’s JNJ-4528 has narrowed as both CAR-T therapies show high response rates in multiple myeloma – and as bispecific antibodies, including Janssen’s teclistamab, edge into the space.
Need a specific report? 1000+ reports available
Buy Reports